These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 16275990)

  • 1. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.
    Mercatante DR; Mohler JL; Kole R
    J Biol Chem; 2002 Dec; 277(51):49374-82. PubMed ID: 12381725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
    Miayake H; Tolcher A; Gleave ME
    J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
    Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
    Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
    Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
    Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
    Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
    Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death.
    Jiang Z; Zheng X; Rich KM
    J Neurochem; 2003 Jan; 84(2):273-81. PubMed ID: 12558990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.
    Castilla C; Congregado B; Chinchón D; Torrubia FJ; Japón MA; Sáez C
    Endocrinology; 2006 Oct; 147(10):4960-7. PubMed ID: 16794010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
    Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
    Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
    Hopkins-Donaldson S; Cathomas R; Simões-Wüst AP; Kurtz S; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2003 Aug; 106(2):160-6. PubMed ID: 12800189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
    Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
    Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
    Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
    Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
    Smythe WR; Mohuiddin I; Ozveran M; Cao XX
    J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
    Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
    Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.